Replies to post #3085 on ImClone Systems Inc (formerly IMCL)

[chkntryakiboy]

Good point, but at least we finally have a piece of terrible press that is screwed up in Imclones favor (unlike anyhting written about the patent issues).

Does Bev have any OS data in first line?!?!?!?

[DewDiligence]

With the addition of only two words, the newswire would be accurate :-)

[Telephonics]

Merck News Release

Merck KGaA: Erbitux Meets Primary Endpoint in First-Line Phase III
Metastatic Colorectal Cancer Study


Darmstadt, Germany, January 10, 2007 – Merck KGaA announced today that a
Phase III study of Erbitux® (cetuximab) plus irinotecan-based therapy met
the primary endpoint of increasing median duration of progression-free
survival in patients with previously untreated metastatic colorectal cancer
(mCRC). This randomized Phase III international trial, known as CRYSTAL
Cetuximab combined with iRinotecan in first line therapY for metaSTatic
colorectAL cancer, studied patients treated with Erbitux plus FOLFIRI
(irinotecan-based chemotherapy) compared with FOLFIRI alone.

The complete news release can be downloaded at the following link:
http://me.merck.de/n/5BE1C55BDCA32E01C125725E004DFBE1/$FILE/crystal_e.pdf